Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,191,518
  • Shares Outstanding, K 117,045
  • Annual Sales, $ 59,610 K
  • Annual Income, $ -262,140 K
  • EBIT $ -182 M
  • EBITDA $ -187 M
  • 60-Month Beta 1.18
  • Price/Sales 19.81
  • Price/Cash Flow N/A
  • Price/Book 7.53

Options Overview Details

View History
  • Implied Volatility 87.73% ( +4.80%)
  • Historical Volatility 62.51%
  • IV Percentile 17%
  • IV Rank 14.28%
  • IV High 323.25% on 11/30/23
  • IV Low 48.49% on 10/09/24
  • Put/Call Vol Ratio 0.13
  • Today's Volume 9
  • Volume Avg (30-Day) 1,413
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 11,742
  • Open Int (30-Day) 22,199

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.28
  • Number of Estimates 3
  • High Estimate -0.22
  • Low Estimate -0.32
  • Prior Year -0.72
  • Growth Rate Est. (year over year) +61.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.03 +26.40%
on 10/22/24
11.44 -11.28%
on 11/08/24
+1.84 (+22.14%)
since 10/21/24
3-Month
8.03 +26.40%
on 10/22/24
11.44 -11.28%
on 11/08/24
+1.81 (+21.70%)
since 08/21/24
52-Week
1.76 +476.70%
on 12/01/23
13.17 -22.93%
on 04/09/24
+8.26 (+437.04%)
since 11/21/23

Most Recent Stories

More News
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

ARQT : 10.06 (-1.18%)
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

ARQT : 10.06 (-1.18%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQT : 10.06 (-1.18%)
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

ARQT : 10.06 (-1.18%)
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

ARQT : 10.06 (-1.18%)
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

ARQT : 10.06 (-1.18%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQT : 10.06 (-1.18%)
3 'Strong-Buy'-Rated Russell 2000 Stocks With 54% to 110% Upside

Investing in these small caps could be rewarding in the long run.

VKTX : 51.37 (-0.31%)
ARQT : 10.06 (-1.18%)
LBPH : 59.77 (+0.02%)
$SPX : 5,903.25 (-0.23%)
5 Breakout Biotech Stocks Leading the Russell 2000 Higher

These small-cap biotech stocks are rallying hard in 2024, and still have room to keep leading the RUT higher.

JANX : 47.60 (-2.78%)
VKTX : 51.37 (-0.31%)
LBPH : 59.77 (+0.02%)
ARQT : 10.06 (-1.18%)
RNA : 43.01 (-1.47%)
S&P Futures Higher After April CPI is Released

June S&P 500 E-Mini futures (ESM24) are trending up +0.45% this morning after April's CPI report was released.

ESM24 : 5,471.89s (-0.09%)
SMCI : 27.14 (+5.19%)
ORCL : 193.50 (+1.44%)
SCHW : 80.66 (+0.25%)
PARA : 10.65 (+0.66%)
CSCO : 57.45 (-0.09%)
GRAB : 5.57 (-1.59%)
MNDY : 268.31 (+3.14%)
EXPN.LN : 3,694.760 (+1.76%)
MRK.D.DX : 138.500 (+0.02%)
NESTE.H.DX : 14.148 (+1.17%)
ARQT : 10.06 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis,...

See More

Key Turning Points

3rd Resistance Point 10.91
2nd Resistance Point 10.67
1st Resistance Point 10.42
Last Price 10.06
1st Support Level 9.93
2nd Support Level 9.69
3rd Support Level 9.44

See More

52-Week High 13.17
Last Price 10.06
Fibonacci 61.8% 8.81
Fibonacci 50% 7.47
Fibonacci 38.2% 6.12
52-Week Low 1.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar